-
Qiagen (QGEN) Reports In-Line Q4 EPS, provides outlook
-
Activist Fivespan Partners takes 6% stake in Appian
-
QIAGEN appoints Mark Stevenson to supervisory board in 2026
-
Deutsche Bank Downgrades Qiagen NV (QGEN) to Hold
-
UBS on Qiagen NV (QGEN): Bid-Ask Spread to Be a Challenge in Potential Takeover Deal
-
Qiagen (QGEN) Paused on Volatility Following M&A Rumor
-
Qiagen (QGEN) Is Said To Weigh Strategic Options Amid Fresh Interest - Bloomberg
-
TD Cowen Reiterates Hold Rating on Novartis (NOVN:SW) (NVS)
-
Qiagen NV (QGEN) PT Lowered to $48 at CFRA
-
Qiagen (QGEN) Tops Q3 EPS by 2c
-
QIAGEN launches automated sexual assault DNA processing kit
-
QIAGEN receives European certification for QIAstat-Dx diagnostic panels
-
QIAGEN receives FDA clearance for higher-throughput diagnostic system
-
QIAGEN issues $750 million convertible bonds due 2032
-
Qiagen (QGEN) Reports In-Line Q2 EPS; offers outlook
-
QIAGEN NV (QIA:GR) (QGEN) PT Raised to EUR50 at Berenberg
-
QIAGEN launches long read sequencing panels for complex genomic analysis
-
Qiagen (QGEN) Appoints Stephen Rusckowski as Board Chair
-
Barclays Starts Qiagen NV (QGEN) at Overweight
-
Qiagen (QGEN) and Gencurix partner to develop oncology assays for QIAcuityDx platform
-
Qiagen (QGEN) and Foresight Diagnostics Enter Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
Qiagen (QGEN) Acquires Genoox AI-powered software
-
Qiagen (QGEN) Tops Q1 EPS by 6c
-
Qiagen (QGEN) Announces Supervisory Board Transition
-
Qiagen (QGEN) to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
-
Qiagen (QGEN) said targeted by activist Fivespan Partners
-
QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook
-
Redburn-Atlantic Downgrades QIAGEN NV (QIA:GR) (QGEN) to Neutral
-
Qiagen (QGEN) Announces New Data Center in Australia/Asia-Pacific Region
-
Qiagen (QGEN) Tops Q4 EPS by 1c; offers guidance
-
Morgan Stanley Downgrades Qiagen NV (QGEN) to Equalweight
-
Jefferies Starts Qiagen NV (QGEN) at Buy
-
HSBC Downgrades Qiagen NV (QGEN) to Hold
-
Neogen Corp. (NEOG) Announces the Appointment of New Board Member
-
Qiagen (QGEN) Tops Q3 EPS by 3c, Beats on Revenue; Offers FY24 EPS Guidance
-
Wolfe Research Upgrades Qiagen NV (QGEN) to Outperform
-
Qiagen NV (QGEN) PT Raised to $46 at UBS
-
Citi Reiterates Buy Rating on Qiagen NV (QGEN)
-
Qiagen (QGEN): Targeting at least 31% CER adjusted operating income margin in 2028

